Journal of Clinical Oncology最新文献

{"title":"Treatment of Pleural Mesothelioma: ASCO Guideline Update.","authors":"Hedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy Chu, Jane E Churpek, Ibiayi Dagogo-Jack, Darren S Bryan, Michael W Drazer, Patrick Forde, Aliya N Husain, Jennifer L Sauter, Valerie Rusch, Penelope A Bradbury, B C John Cho, Marc de Perrot, Azam Ghafoor, David L Graham, Ola Khorshid, Alexandra Lebensohn, Julie White, Raffit Hassan","doi":"10.1200/JCO-24-02425","DOIUrl":"10.1200/JCO-24-02425","url":null,"abstract":"<p><strong>Purpose: </strong>To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).</p><p><strong>Methods: </strong>ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.</p><p><strong>Results: </strong>The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.</p><p><strong>Recommendations: </strong>Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1006-1038"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.","authors":"Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, Jack H Peplinski, Todd A Alonzo, Derek Stirewalt, Megan Othus, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils von Neuhoff, Henrik Hasle, Dirk Reinhardt, Soheil Meshinchi, Franco Locatelli, Martina Pigazzi","doi":"10.1200/JCO-24-01715","DOIUrl":"10.1200/JCO-24-01715","url":null,"abstract":"<p><strong>Purpose: </strong>Several genomic subsets of <i>NPM1</i> mutations with varying sequences (type A, B, D, etc) have been identified. Despite molecular heterogeneity, <i>NPM1</i> mutations cumulatively portend a more favorable outcome, but biology and prognostic implications of different genomic subsets have not been extensively studied. In this multicentric study, we investigated the impact of <i>NPM1</i> genotypes on patient's outcomes and interrogated the underlying biology of the different subtypes.</p><p><strong>Materials and methods: </strong>Of more than 4,000 patients enrolled in multiple pediatric cooperative (AIEOP, BFM, ELAM02, NOPHO, DCOG, and COG trials), or adult (SWOG) trials, 348 pediatric and 75 adult AML patients with known <i>NPM1</i> genotype and available outcome were selected for this study. Diverse <i>NPM1</i> variants were correlated with the probabilities of overall survival (OS) and event-free survival. Nuclear localization and translational efficiency of the <i>NPM1</i> variants was studied.</p><p><strong>Results: </strong>Evaluation of clinical outcome on the basis of <i>NPM1</i> genotypes showed that patients with type A, B, and other rare variants had similarly favorable outcomes, whereas those with type D had a significantly worse outcome (OS of 63% for type D <i>v</i> 86% for type non-D, <i>P</i> = .005). Multivariate analysis confirmed type D as an independent prognostic factor associated with inferior OS (hazard ratio, 3; <i>P</i> = .005). In vitro, we demonstrated that in type D versus type A synonymous variants, codon optimality plays major roles in determining gene expression levels, and translation efficiency, which resulted in a more expressed <i>NPM1-D</i> mRNA and protein, mediating peculiar mitochondrial gene expression.</p><p><strong>Conclusion: </strong>The evaluation of specific <i>NPM1</i> genotypes identified AML patients with type D mutations being significantly associated with inferior outcomes, suggesting a reclassification of D cases to higher-risk groups.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"972-984"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.","authors":"Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer, Allison Meisner, Gabriel N Hortobagyi, Steven Shak, James M Rae, Rick Baehner, Priyanka Sharma, Kevin M Kalinsky","doi":"10.1200/JCO-24-01507","DOIUrl":"10.1200/JCO-24-01507","url":null,"abstract":"<p><strong>Purpose: </strong>Clinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence risk and chemotherapy benefit predictions by menopausal status for patients with HR+/human epidermal growth factor receptor 2-negative, lymph node-positive breast cancer by integrating the RS result with clinicopathological factors (grade, tumor size, age).</p><p><strong>Methods: </strong>We used patient-level data from 5,283 patients treated with chemoendocrine therapy (CET) versus endocrine therapy alone (ET) in the S1007 (N = 4,916) and S8814 (N = 367) trials to develop the tool. Cox proportional hazards regression models stratified by trial were used to estimate 5-year invasive disease-free survival for pre- and postmenopausal woman, respectively. The integrated RSClinN+ model was compared with RS alone and clinicopathological models using likelihood ratio tests. Absolute CET benefit was estimated as the difference between ET and CET risk estimates. Validation of RSClinN+ was performed in 592 patients with node-positive disease in the Clalit Health Services registry.</p><p><strong>Results: </strong>RSClinN+ provides better prognostic information than RS model alone (premenopausal <i>P</i> = .034; postmenopausal <i>P</i> < .001) or clinicopathological model alone (premenopausal <i>P</i> = .002; postmenopausal, <i>P</i> < .001). In postmenopausal women, RS showed interaction with CET benefit (<i>P</i> = .016), with RSClinN+ absolute CET benefit ranging from <0.1% to 21.5% over RS ranges 0-50. In premenopausal patients with RS ≤25, there was no significant interaction between RS and CET benefit. In external validation, RSClinN+ risk estimates were prognostic (hazard ratio, 1.75 [95% CI, 1.38 to 2.20]) and concordant with observed risk (Lin's concordance, 0.92).</p><p><strong>Conclusion: </strong>RSClinN+ provides improved estimates of prognosis and absolute CET benefit for individual patients compared with RS or with clinical data alone and could be used in patient counseling.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"919-928"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.","authors":"Leo Mascarenhas, Steven G DuBois, Catherine M Albert, Stefan Bielack, Daniel Orbach, Noah Federman, Birgit Geoerger, Ramamoorthy Nagasubramanian, Yizhou Zhang, Julia Chisholm, Soledad Gallego Melcon, Hiroaki Goto, Daniel A Morgenstern, Cormac Owens, Alberto S Pappo, Sébastien Perreault, Johannes H Schulte, Neerav Shukla, Christian Michel Zwaan, Natascha Neu, Vadim Bernard-Gauthier, Esther De La Cuesta, Cornelis M van Tilburg, Theodore W Laetsch","doi":"10.1200/JCO-25-00252","DOIUrl":"10.1200/JCO-25-00252","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1046"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accurate Determinants of Outcome in ALL.","authors":"Gejing Zhu","doi":"10.1200/JCO-24-01776","DOIUrl":"10.1200/JCO-24-01776","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1039"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?","authors":"Aaron J Scott, Erin B Kennedy, Sepideh Gholami","doi":"10.1200/JCO-24-02435","DOIUrl":"https://doi.org/10.1200/JCO-24-02435","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"43 8","pages":"1043-1044"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?","authors":"Mahsoem Ali, Lenka N C Boyd, Elisa Giovannetti, Geert Kazemier","doi":"10.1200/JCO-24-02080","DOIUrl":"https://doi.org/10.1200/JCO-24-02080","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"43 8","pages":"1041-1043"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.","authors":"Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Charisse Capadona, Sarima Subzwari, Natasha Galasso, Jinshu Yang, Michelle Post, Alexander Boardman, Philip Caron, Kevin David, Zachary Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Paul Hamlin, Steven M Horwitz, Andrew M Intlekofer, William Johnson, Anita Kumar, Jennifer Lue, Ariela Noy, Colette Owens, M Lia Palomba, Gilles A Salles, Raphael Steiner, Robert Stuver, Santosha Vardhana, Joachim Yahalom, Ahmet Dogan, Andrew D Zelenetz, Heiko Schöder, Alison J Moskowitz","doi":"10.1200/JCO-24-01278","DOIUrl":"10.1200/JCO-24-01278","url":null,"abstract":"<p><strong>Purpose: </strong>We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).</p><p><strong>Methods: </strong>Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle. A geriatric assessment was performed before therapy initiation. The primary end point was progression-free survival (PFS).</p><p><strong>Results: </strong>Patient characteristics (N = 40) included median age of 66 years (range, 60-78 years) with 38% ≥70 years, 78% with stage III/IV disease, 68% with International Prognostic Score of ≥3, 82% dependent in ≥1 activities of daily living, 23% dependent in ≥1 instrumental activities of daily living, 50% with impaired timed up and go test, and 40% with polypharmacy. Among 37 response-evaluable patients, the median follow-up was 49 months and 3-year PFS and overall survival (OS) were 79% and 97%, respectively. Overall, 50% patients experienced grade 3/4 treatment-related adverse events (TRAEs), including febrile neutropenia in 8%. Four (10%) patients stopped therapy due to TRAEs. There was no correlation between baseline geriatric impairments and survival outcomes or toxicities. Positron emission tomography-2 was not predictive of PFS or OS.</p><p><strong>Conclusion: </strong>N-AVD is a highly effective and well-tolerated frontline regimen in OA with cHL across a wide range of geriatric impairments.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"985-993"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors.","authors":"David D Ma, Zhixin Liu, Kimberley Au, Mei Tran, Crisbel M Artuz, Matthew Greenwood, Ian Bilmon, David Kliman","doi":"10.1200/JCO.24.00333","DOIUrl":"10.1200/JCO.24.00333","url":null,"abstract":"<p><strong>Purpose: </strong>Because of advances in hematopoietic cell transplant (HCT), meeting the long-term health needs of increasing numbers of HCT survivors remains challenging. This multicenter trial aimed to assess the short- and long-term effects of an exercise and mindfulness intervention delivered by telehealth.</p><p><strong>Methods: </strong>One hundred thirty-nine participants >6 months post-HCT were randomly assigned 1:1 to a 6-week personalized exercise and mindfulness training with three motivation sessions at 3-6 months via an online meeting platform or usual care. Physical and quality-of-life (QOL) assessments were conducted online for 12 months. The primary end point was the 6-minute walk test (6-MWT) at 3 months.</p><p><strong>Results: </strong>The median time post-HCT was 21 months (range, 7-67 months). Improvement in mean difference of 6-MWT was found in the intervention group compared with control (intention-to-treat) at 3 months (51.4 m [95% CI, 27.3 to 75.5]; <i>P</i> < .001; effect size [ES], 0.52) and was maintained at 12 months (59.3 m, <i>P</i> = .003; ES, 0.60). Sustained improvements in mean difference for sit-to-stand (STS) at 3 and 12 months were seen. There were no significant changes in hand grip strength or QOL outcomes between groups. A significant difference in serum soluble intercellular adhesion molecule-1 (sICAM-1) concentration was observed between the intervention and control groups in the exploratory study. No intervention adverse events were found.</p><p><strong>Conclusion: </strong>The supervised multimodal telehealth intervention provided clinically meaningful and durable improvement of physical capacity in HCT survivors. This home-based program has the potential to provide an unmet need for HCT survivors. Similar programs may benefit survivors of other cancers, organ transplants, and chronic disorders.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"949-959"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.","authors":"Sapna P Patel, Rahul A Sheth, Christina Davis, Theresa Medina","doi":"10.1200/JCO-24-01802","DOIUrl":"10.1200/JCO-24-01802","url":null,"abstract":"<p><p><i>The</i> Oncology Grand Rounds <i>series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in</i> Journal of Clinical Oncology<i>, to patients seen in their own clinical practice</i>.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"907-911"},"PeriodicalIF":42.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}